Zobrazeno 1 - 10
of 14
pro vyhledávání: '"AnaMaria Lopez"'
Autor:
Brooke Worster, Lauren Waldman, Gregory Garber, Tingting Zhan, AnaMaria Lopez, Olivia Trachtenberg, Nathan Handley, Kristin L. Rising, Valerie Csik, Amy Leader
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2842-2849 (2023)
Abstract Introduction Telehealth (TH) utilization in cancer care prior to COVID‐19 was variable. Research highlights disparities in access determined by socioeconomic factors including education, income, race, and age. In response to COVID‐19 and
Externí odkaz:
https://doaj.org/article/f87b7cd17f41451cb56dc6a9972e8bab
Autor:
Brooke Worster, Lauren Waldman, Gregory Garber, Tingting Zhan, AnaMaria Lopez, Olivia Trachtenberg, Nathan Handley, Kristin L. Rising, Valerie Csik, Amy Leader
Publikováno v:
Cancer Medicine. 12:2842-2849
Telehealth (TH) utilization in cancer care prior to COVID-19 was variable. Research highlights disparities in access determined by socioeconomic factors including education, income, race, and age. In response to COVID-19 and these disparities, we ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ff99d4c5cfff1ab56292ebbf0e07db
https://doi.org/10.1002/cam4.5176
https://doi.org/10.1002/cam4.5176
Autor:
Sameh Gomaa, AnaMaria Lopez, Rachel Slamon, Rita Smith, Elma Telushi, Emmanuel Lapitan, Ginah Nightingale, Suzanne Miller, Kuang-Yi Wen
Purpose Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b20210156ae14095a7a25ccc6f303b67
https://doi.org/10.21203/rs.3.rs-2497342/v1
https://doi.org/10.21203/rs.3.rs-2497342/v1
Autor:
Weelic Chong, Rui Luo, Zhenchao Zhang, Maysa Abu-Khalaf, Daniel Silver, Frederick Fellin, Rebecca Jaslow, AnaMaria Lopez, Terrence Cescon, Ronald Myers, Mariel Becker, Qiang Wei, Bingshan Li, Chun Wang, Hushan Yang
Publikováno v:
Cancer Research. 83:P5-06
Background: Structural variation is a hallmark of breast cancer. Previous single-cell genomic analysis of 10 untreated early-stage primary TNBC tumors identified only one or two subclones per tumor, found that copy number variation (CNV) occurs early
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48d225f8a86142fd3bf7e34625a3c226
https://doi.org/10.1158/1538-7445.sabcs22-p5-06-02
https://doi.org/10.1158/1538-7445.sabcs22-p5-06-02
Autor:
Rui Luo, Weelic Chong, Zhenchao Zhang, Maysa Abu-Khalaf, Daniel Silver, Frederick Fellin, Rebecca Jaslow, AnaMaria Lopez, Terrence Cescon, Kevan Ip, Ronald Myers, Qiang Wei, Bingshan Li, Chun Wang, Hushan Yang
Publikováno v:
Cancer Research. 83:P5-06
Background: Although different patterns and changes in DNA methylation play an important role in cancer progression and tumor subtype differentiation, methylation remains relatively less understood in the context of tumor heterogeneity. Intra-tumor h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a3b2db119a3902f41d3a6161c7f461e
https://doi.org/10.1158/1538-7445.sabcs22-p5-06-05
https://doi.org/10.1158/1538-7445.sabcs22-p5-06-05
Autor:
Yang, Maysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, Rui Luo, Weelic Chong, Daniel P. Silver, Frederick Fellin, Rebecca Jaslow, AnaMaria Lopez, Terrence Cescon, Wei Jiang, Ronald Myers, Qiang Wei, Bingshan Li, Massimo Cristofanilli, Hushan
Publikováno v:
Cancers; Volume 14; Issue 12; Pages: 2872
Previously undescribed molecular mechanisms of resistance will emerge with the increased use of cyclin-dependent kinase 4/6 inhibitors in clinical settings. To identify genomic aberrations in circulating tumor DNA associated with treatment resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::176571153bc48beda2a4bef97df414e5
Publikováno v:
Cancer Research. 83:P6-05
Background: A survivorship care plan (SCP) is a detailed cancer care summary and future care plan that is generally given to a patient upon completion of adjuvant treatment for a cancer diagnosis. The initial goals of SCPs were to educate patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d58f4ae2df1dda70dac8bfff109f29bf
https://doi.org/10.1158/1538-7445.sabcs22-p6-05-24
https://doi.org/10.1158/1538-7445.sabcs22-p6-05-24
Autor:
Maysa, Abu-Khalaf, Chun, Wang, Zhenchao, Zhang, Rui, Luo, Weelic, Chong, Daniel P, Silver, Frederick, Fellin, Rebecca, Jaslow, AnaMaria, Lopez, Terrence, Cescon, Wei, Jiang, Ronald, Myers, Qiang, Wei, Bingshan, Li, Massimo, Cristofanilli, Hushan, Yang
Publikováno v:
Cancers. 14(12)
Previously undescribed molecular mechanisms of resistance will emerge with the increased use of cyclin-dependent kinase 4/6 inhibitors in clinical settings. To identify genomic aberrations in circulating tumor DNA associated with treatment resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfea74ff7f57f445bb62dd5f1721918d
https://pubmed.ncbi.nlm.nih.gov/35740538
https://pubmed.ncbi.nlm.nih.gov/35740538
Autor:
Chun Wang, Frederick M. Fellin, Darayus Toorkey, Kaelan Yao, Neha Pancholy, Saveri Bhattacharya, Maysa M. Abu-Khalaf, Ronald E. Myers, Rebecca Jaslow, Daniel P. Silver, Zhong Ye, AnaMaria Lopez, Hushan Yang, Zhenchao Zhang
Publikováno v:
Cancer Research. 80:P6-10
Background: Circulating tumor cells (CTCs) and their clusters (CTC-clusters) are promising prognostic markers in breast cancer. Recently studies showed that platelets interact with tumor cells in the circulation and promote metastasis. However, no st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26723094f401f31b1a54ab3ec007a1bf
https://doi.org/10.1158/1538-7445.sabcs19-p6-10-23
https://doi.org/10.1158/1538-7445.sabcs19-p6-10-23
Autor:
Chun Wang, Bingshan Li, Zhong Ye, Saveri Bhattacharya, Terrence P. Cescon, Hushan Yang, AnaMaria Lopez, Frederick M. Fellin, Maysa M. Abu-Khalaf, Daniel P. Silver, Ronald E. Myers, Qiang Wei, Zhenchao Zhang, Rebecca Jaslow
Publikováno v:
Cancer Research. 80:P4-10
Background: Palbociclib is the first-in-class cyclin dependent kinase (CDK) 4/6 inhibitor approved for the treatment of patients (pts) with hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative metastatic breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9da4c38b08e44b661776fa5ce8adaf2a
https://doi.org/10.1158/1538-7445.sabcs19-p4-10-27
https://doi.org/10.1158/1538-7445.sabcs19-p4-10-27